PAVmed Inc. Announces Upcoming Business Update Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) is preparing to engage with its investors through a key conference call and webcast. This anticipated event is scheduled for 8:30 AM Eastern Time on May 15, 2025. The company, a significant player in the medical technology field, will be sharing vital insights about its operational strategies and advancements in various sectors, including medical devices and diagnostics.
Details of the Conference Call and Webcast
During this momentous call, Dr. Lishan Aklog, the Chairman and CEO of PAVmed, will take the opportunity to present a comprehensive overview of the company's operations and its strategic direction for the future. Joining him will be Dennis McGrath, the President and CFO, who will delve into the financial results for the first quarter of 2025. This dual insight from the leadership team aims to provide stakeholders with a well-rounded understanding of where PAVmed is currently positioned and where it aims to head.
Accessing the Webcast
Investors looking to participate can conveniently access the webcast through PAVmed's investor relations section on their official website. For those who prefer to join via telephone, U.S. callers can dial 1-800-836-8184, while international callers can reach out at 1-646-357-8785. When prompted, attendees are encouraged to cite "PAVmed Business Update" to ensure their admission into the call.
Replay Information
For anyone unable to attend the live session, a replay will be available for 30 days post-event on the company’s investor relations page. This allows all interested parties to stay informed of PAVmed's latest developments at their convenience.
About PAVmed Inc.
PAVmed Inc. stands as a trailblazing diversified commercial-stage medical technology company. Its specialties span across medical devices, diagnostics, and the growing digital health sector. PAVmed's subsidiary, Lucid Diagnostics (Nasdaq: LUCD), plays a crucial role in cancer prevention, offering innovative products such as the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which are important tools for detecting precancerous conditions early, thus potentially saving numerous lives.
Innovations in Cancer Care
Moreover, PAVmed’s other subsidiary, Veris Health Inc., focuses on personalized cancer care through advanced technologies such as remote patient monitoring using biologic sensors. They are also in the process of developing an implantable physiological monitor, which works in tandem with chemotherapy ports, highlighting their commitment to integrating technology into cancer treatment for improved outcomes.
Concluding Thoughts
With the upcoming business update conference call, PAVmed continues its tradition of transparency with investors, showcasing its growth journey and commitment to innovative healthcare solutions. This call presents an excellent opportunity for stakeholders to engage directly with the company's leadership as they chart the path forward.
Frequently Asked Questions
What is the date of PAVmed's upcoming conference call?
The conference call is scheduled for May 15, 2025, at 8:30 AM Eastern Time.
Who will be speaking during the conference call?
Dr. Lishan Aklog, the CEO, and Dennis McGrath, the CFO, will be leading the discussions.
How can I listen to the conference call?
Investors can join the webcast via PAVmed's investor relations website, or by phone using the specified numbers for U.S. and international callers.
Will a replay be available after the call?
Yes, a replay will be accessible for 30 days following the live event on the investor relations section of the PAVmed website.
What are some of PAVmed's key products?
PAVmed’s subsidiary, Lucid Diagnostics, offers the EsoGuard test and EsoCheck device, both aimed at early detection of esophageal cancer risks.
